Lung Cancer Clinical Trial

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Summary

This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy

View Eligibility Criteria

Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria

Histologically or cytologically-documented Stage IV A/B non-small cell lung Cancer, stage IIIB/C disease failed concurrent chemoRT.
ECOG Performance Status of ≤ 1.
Radiologically-documented disease progression on one anti-PD-1/anti-PD-L1 therapy and one platinum-based doublet regimen given either concurrently or sequentially within 90 days after the last dose of anti-PD-(L)1.
All participants must have tumor tissue submitted prior to randomization, either a recent archival sample obtained on/after the date of disease progression of the last prior anticancer therapy and within 3 months prior to enrollment, or a fresh biopsy obtained during the screening period.
Prior toxicities must have resolved to grade ≤1.
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test and must not be breastfeeding.
Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception. In addition, male participants must be willing to refrain from sperm donation during this time and must agree to follow instructions for method(s) of contraception. Azoospermic males are exempt from contraceptive requirements as well as WOCBP who are continuously not heterosexually active, however, a pregnancy test will still be required.

Exclusion Criteria

Prior treatment with Docetaxel.
Untreated CNS metastases, carcinomatous meningitis or leptomeningeal metastases.
Any tumor invading the Superior Vena Cava other blood vessel, GI Tract or Trachea.
EGFR mutations, ALK translocations, ROS1 translocations which are sensitive to inhibitor therapy.
History of cerebrovascular accident and coagulation disorders.
Participants with interstitial lung disease, history of cerebrovascular accident or history of abdominal fistula, gastrointestinal perforation, bowel obstruction, intra-abdominal abscess or grade 3-4 bleeding event within 6 months prior to randomization.
Known toxicity on prior checkpoint inhibitor treatment.
Participants who received more than one line of anti- PD-1/PD-L1 treatment.
Participants who received previous CTLA-4 inhibitor treatment.
Participants with known BRAF V600E mutation which are sensitive to available targeted inhibitor therapy are excluded.
Other protocol-defined Inclusion/Exclusion criteria apply.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Study ID:

NCT04151563

Recruitment Status:

Withdrawn

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 23 Locations for this study

See Locations Near You

Local Institution
Detroit Michigan, 48201, United States
Local Institution
Ciudad Autónoma De Buenos Aires Buenos Aires, 1426, Argentina
Local Institution
Buenos Aires Distrito Federal, 1431, Argentina
Local Institution
Buenos Aires Distrito Federal, C1199, Argentina
Local Institution
Caba Distrito Federal, 1430, Argentina
Local Institution
Capital Distrito Federal, C1280, Argentina
Local Institution
Charleroi , 6000, Belgium
Local Institution
Gilly , 6060, Belgium
Local Institution
Leuven , 3000, Belgium
Local Institution
Copenhagen Ø , 2100, Denmark
Local Institution
Athens , 11527, Greece
Local Institution
Neo Faliro , 18547, Greece
Local Institution
Torreon Coahuila, 27010, Mexico
Local Institution
Ciudad de México Distrito Federal, 03240, Mexico
Local Institution
Zapopan Jalisco, 44280, Mexico
Local Institution
Heroica Puebla de Zaragoza Puebla, 72530, Mexico
Local Institution
Amsterdam , 1066 , Netherlands
Local Institution
Rotterdam , 3015 , Netherlands
Local Institution
Oslo , 0379, Norway
Local Institution
Warszawa Mazowieckie, 02-78, Poland
Local Institution
Krakow , 30-68, Poland
Local Institution
Craiova , 20034, Romania
Local Institution
Timisoara , 30069, Romania

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Study ID:

NCT04151563

Recruitment Status:

Withdrawn

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.